AIM To explore the therapeutic effects of sacubitril/valsartan versus valsartan on cardiac functions and qualities of life in post-acute myocardial infarction (AMI) heart failure patients.
METHODS From July 2018 to July 2019, 146 post-AMI heart failure patients were selected and randomly divided into valsartan group (n = 71) and sacubitril/valsartan group (n = 75). The patients were followed up for 1 year and their chocardiography, serum creatinine, blood urea nitrogen, NT-proBNP and quality of life-related parameters were collected at 1 month and 1 year.
RESULTS After 1 month treatment, the improvements of NT-proBNP, 6 minutes’ walking distance, NYHY classification and MLHFQ scale in sacubitril/valsartan group were significantly larger than those in valsartan group (P < 0.05). After 1 year treatment, the improvements of LVEF and ESV in sacubitril/valsartan group were also significantly larger than those in valsartan group (P < 0.01). And so were the improvements in NT-proBNP, 6 minutes’ walking distance, NYHY classification and MLHFQ scale (P < 0.05).
CONCLUSION Post-AMI patients benefit more from sacubitril/valsartan than valsartan for their cardiac functions and qualities of life.
DownLoad: